Skip to Content

ReNeuron Group PLC RNUGF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

Pencoed Business Park
Pencoed, Bridgend, CF35 5HY, United Kingdom
T +44 2038198400
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Mar 31, 2021
Stock Type
Employees 38